These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin. Kovar M; Tomala J; Chmelova H; Kovar L; Mrkvan T; Joskova R; Zakostelska Z; Etrych T; Strohalm J; Ulbrich K; Sirova M; Rihova B Cancer Res; 2008 Dec; 68(23):9875-83. PubMed ID: 19047168 [TBL] [Abstract][Full Text] [Related]
44. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Yang Y; Pan D; Luo K; Li L; Gu Z Biomaterials; 2013 Nov; 34(33):8430-43. PubMed ID: 23896006 [TBL] [Abstract][Full Text] [Related]
45. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators. Ríhová B; Jelínková M; Strohalm J; Subr V; Plocová D; Hovorka O; Novák M; Plundrová D; Germano Y; Ulbrich K J Control Release; 2000 Feb; 64(1-3):241-61. PubMed ID: 10640661 [TBL] [Abstract][Full Text] [Related]
46. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies. Li L; Zhou M; Huang Y Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570 [TBL] [Abstract][Full Text] [Related]
47. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates. He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288 [TBL] [Abstract][Full Text] [Related]
48. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity. Mrkvan T; Sirova M; Etrych T; Chytil P; Strohalm J; Plocova D; Ulbrich K; Rihova B J Control Release; 2005 Dec; 110(1):119-29. PubMed ID: 16269198 [TBL] [Abstract][Full Text] [Related]
52. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660 [TBL] [Abstract][Full Text] [Related]
53. The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization. Chytil P; Šírová M; Koziolová E; Ulbrich K; Říhová B; Etrych T Physiol Res; 2015; 64(Suppl 1):S41-9. PubMed ID: 26447594 [TBL] [Abstract][Full Text] [Related]
54. Comparison between linear and star-like HPMA conjugated pirarubicin (THP) in pharmacokinetics and antitumor activity in tumor bearing mice. Nakamura H; Koziolová E; Etrych T; Chytil P; Fang J; Ulbrich K; Maeda H Eur J Pharm Biopharm; 2015 Feb; 90():90-6. PubMed ID: 25460144 [TBL] [Abstract][Full Text] [Related]
55. Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. Pimm MV; Perkins AC; Strohalm J; Ulbrich K; Duncan R J Drug Target; 1996; 3(5):385-90. PubMed ID: 8866657 [TBL] [Abstract][Full Text] [Related]
56. Interaction of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates with human liver microsomal cytochromes P450: comparison with free doxorubicin. Masek V; Anzenbacherová E; Etrych T; Strohalm J; Ulbrich K; Anzenbacher P Drug Metab Dispos; 2011 Sep; 39(9):1704-10. PubMed ID: 21642392 [TBL] [Abstract][Full Text] [Related]
57. Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy. Pan H; Sima M; Yang J; Kopeček J Macromol Biosci; 2013 Feb; 13(2):155-60. PubMed ID: 23339052 [TBL] [Abstract][Full Text] [Related]
58. Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro. Subr V; Sivák L; Koziolová E; Braunová A; Pechar M; Strohalm J; Kabešová M; Ríhová B; Ulbrich K; Kovář M Biomacromolecules; 2014 Aug; 15(8):3030-43. PubMed ID: 24978588 [TBL] [Abstract][Full Text] [Related]
59. The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line. Kovár L; Strohalm J; Chytil P; Mrkvan T; Kovár M; Hovorka O; Ulbrich K; Ríhová B Bioconjug Chem; 2007; 18(3):894-902. PubMed ID: 17402705 [TBL] [Abstract][Full Text] [Related]
60. Polyacetal-doxorubicin conjugates designed for pH-dependent degradation. Tomlinson R; Heller J; Brocchini S; Duncan R Bioconjug Chem; 2003; 14(6):1096-106. PubMed ID: 14624622 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]